text Therapeutics (US:CNTX) Globenewswireยท2025-06-02 11:30Core Insights - Context Therapeutics Inc. is advancing CTIM-76, a Claudin 6 x CD3 T cell engager, in a Phase 1 clinical trial targeting ovarian, endometrial, and testicular cancers, with initial data expected in the first half of 2026 [1][7]. Group 1: Clinical Trial Details - The Phase 1 trial is an open-label, dose escalation and expansion study aimed at evaluating the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic cancers [2]. - The trial plans to enroll up to 70 patients and will assess safety, tolerability, pharmacokinetics, and anti-tumor activity through various metrics [2]. Group 2: Presentation Information - A poster presentation titled "A phase 1, first-in-human study of CTIM-76" will be showcased at the 2025 ASCO Annual Meeting on June 2, 2025 [3]. - The presentation will be available on the company's website under the "Publications and Posters" section [3]. Group 3: Product Overview - CTIM-76 is a bispecific antibody that targets CLDN6, which is prevalent in various solid tumors, including ovarian and endometrial cancers [4]. - Preclinical studies indicate that CTIM-76 may offer convenient dosing with low immunogenicity risk and scalable manufacturing capabilities [4]. Group 4: Company Background - Context Therapeutics Inc. is focused on developing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [5]. - The company is headquartered in Philadelphia and actively engages with the investment community through various channels [5].